How do I buy Alnylam (ALNY) stock?

Buying Alnylam (ALNY) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and verify your identity. Make a deposit. Search for the code "ALNY", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy ALNY by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

How do I tell if ALNY is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Alnylam (ALNY) Stock

Q: What is the minimum investment for ALNY on Gotrade?

On Gotrade , you don't have to buy a full share. With fractional shares, you can start investing in Alnylam from just $1. A small budget shouldn't stop you from building a US stock portfolio.

NSQ · ALNY

Trade ALNY

Key stats

Market cap: $21.41B
Price / Earnings ratio: 7.5x
EPS (TTM): $20.38
Volume: Loading
52-week high: $479.79
52-week low: $149.18
EPS vs analyst estimate: +135.8%Q3 FY25 · $2.90 vs $1.23

Source: third-party data provider, as of November 13, 2026

EPS estimate: analyst consensus

Compare with ALNY

Technical indicators

RSI 14: 28.61
MACD 12/26/9: -21.41
EMA 9 of MACD: -18.08
MACD histogram: -3.32
SMA 50: $223.45; Price below SMA 50
EMA 50: $212.51; Price below EMA 50
SMA 200: $277.36; Price below SMA 200
EMA 200: $282.87; Price below EMA 200

Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.

Analyst ratings

Analyst consensus: Buy

Based on 17 analyst ratings

Strong Sell0

Sell0

Hold5

Buy12

Strong Buy0

Third-party analyst opinion, not a recommendation from Gotrade.

Financials

Performance

Revenue

Net income

Net margin %

2021

2022

2023

2024

2025

4B3B1B0

Debt & Balance Sheet

Total assets

Total liabilities

2021

2022

2023

2024

2025

6B4B2B0

Revenue to Profit

2025

$3.7B

Revenue

$0.0

Cost of revenue

$3.0B

Gross profit

$0.0

Operating expenses

$313.7M

Net income

Earnings

EPS forecast

Actual EPS

$2.90

$1.23

Q3FY25

$1.46

Q4FY25

$1.83

Q1FY26

$1.56

Q2FY26

$1.99

Q3FY26

The market is expecting earnings per share of $1.99 for this quarter. The company has not yet shared when it is announcing earnings.

Source: third-party data provider

About Alnylam

Alnylam has led the translation of RNAi (RNA interference) from Nobel Prize-winning discovery into an innovative, entirely new class of medicines. Founded in 2002 by a team of distinguished life sciences leaders, Alnylam’s vision is to harness the potential of RNAi therapeutics to transform the lives of people living with diseases for which there are limited or inadequate treatment options.

SectorHealthcare

IndustryBiotechnology

Employees2,500

CEODr. Yvonne L. Greenstreet M.B.A., M.D.

IPO DateMay 28, 2004

HeadquartersCambridge, MA

Key Executives

Name	Title	Year Born
Dr. Yvonne L. Greenstreet M.B.A., M.D.	CEO & Director	1963
Mr. Jeffrey V. Poulton M.B.A.	CFO & Executive VP	1968
Dr. Phillip A. Sharp Ph.D.	Co-Founder, Member of the Scientific Advisory Board	1945
Mr. Bryan Andrew Supran J.D.	Chief Legal Officer	1970
Dr. Pushkal P. Garg M.D.	Executive VP & Chief Research & Development Officer	1968
Mr. Tolga Tanguler M.B.A.	Executive VP & Chief Commercialization Officer	1973
Mr. Timothy J. Maines	Chief Technical Operations & Quality Officer	—
Dr. Kevin Joseph Fitzgerald Ph.D.	Executive VP, Chief Scientific Officer and Head of Early Research & Early Development	1968
Mr. Joshua Brodsky	Vice President of Investor Relations	—
Mr. Piyush Sharma J.D.	Chief Ethics & Compliance Officer	—

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2021											+6.1	-5.8
2022	-20.9	+8.9	+0.5	-21.2	-9.5	+18.5	-4.2	+47.7	-5.2	+5.3	+3.5	+7.9
2023	-3.1	-14.9	+2.5	-0.7	-8.4	+0.7	+3.0	+4.6	-12.0	-15.2	+7.2	+11.7
2024	-11.3	-13.6	-2.1	-6.1	-1.0	+61.5	-2.4	-2.2	+8.4	-3.4	-7.6	-7.0
2025	+16.1	-10.1	+10.9	+2.9	+19.4	+6.5	+21.8	+11.1	+2.0	-1.0	+4.0	-12.5
2026	-15.5	-1.8	+1.8	-5.9	+2.0	+1.8	-31.9	+9.2	+0.3	-28.6	+1.2

Stocks in the same sector

Vertex Pharmaceuticals

ABEO

Abeona Therapeutics Inc.

FAQ

Buying Alnylam (ALNY) stock is now easy and instant through the Gotrade app.

Download the Gotrade app from the App Store or Google Play.
Create an account and verify your identity.
Make a deposit.
Search for the code "ALNY", then tap "Trade".
Tap the "Buy" button.
Enter the amount you want to buy. You have two options:
1. Buy ALNY by number of shares.
2. Buy fractional shares in dollars, starting from $1.
Swipe up to confirm your order, and you're done!

On Gotrade, you don't have to buy a full share. With fractional shares, you can start investing in Alnylam from just $1. A small budget shouldn't stop you from building a US stock portfolio.

At the moment, Alnylam (ALNY) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track ALNY's performance via the price chart in the Gotrade app.

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

You can place an order any time. It goes through when the US market (NYSE/NASDAQ) opens: 9:30 AM to 4:00 PM New York time, Monday to Friday. Pre-market and after-hours trading are open too.

The market is closed on US public holidays. The Gotrade app shows whether the market is open.

There's no single perfect answer, but common approaches include:

Compare valuation (e.g., P/E, P/S) against historical averages or competitors.
Review revenue and earnings growth.
Check margins and cash flow.
Evaluate business outlook and the company's position within its industry.

You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Trade Faster. Easier. Smarter.

#ReadyGoTrade

Welcome Reward up to $1,888

Create an account and trade US stocks on Gotrade

Download app

*Terms & conditions apply

Alnylam (ALNY) Stock

Key stats

Compare with ALNY

Recent news

Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA® (vutrisiran) at AHA and ISA 2026

Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA® (vutrisiran) at AHA and ISA 2026

ALNY Stock Down 25% Despite Q3 Earnings Beat on Demand Growth Concerns

ALNY Stock Down 25% Despite Q3 Earnings Beat on Demand Growth Concerns

ALNY Stock Hits Fresh 52-Week Low On Medicare Access Worries And Pipeline Delays

ALNY Stock Hits Fresh 52-Week Low On Medicare Access Worries And Pipeline Delays

Alnylam Pharmaceuticals Q3 Earnings Call Highlights

Alnylam Pharmaceuticals Q3 Earnings Call Highlights

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA® (vutrisiran) at AHA and ISA 2026

Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA® (vutrisiran) at AHA and ISA 2026

ALNY Stock Down 25% Despite Q3 Earnings Beat on Demand Growth Concerns

ALNY Stock Down 25% Despite Q3 Earnings Beat on Demand Growth Concerns

ALNY Stock Hits Fresh 52-Week Low On Medicare Access Worries And Pipeline Delays

ALNY Stock Hits Fresh 52-Week Low On Medicare Access Worries And Pipeline Delays

Alnylam Pharmaceuticals Q3 Earnings Call Highlights

Alnylam Pharmaceuticals Q3 Earnings Call Highlights

Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top Estimates

Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top Estimates

Compared to Estimates, Alnylam (ALNY) Q3 Earnings: A Look at Key Metrics

Compared to Estimates, Alnylam (ALNY) Q3 Earnings: A Look at Key Metrics

Alnylam Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Period Progress

Alnylam Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Period Progress

Alnylam (ALNY) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Alnylam (ALNY) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Alnylam Reports Up to 83% Huntingtin Reduction, Eyes 2027 Pivotal Trial

Alnylam Reports Up to 83% Huntingtin Reduction, Eyes 2027 Pivotal Trial

Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington's Disease

Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington's Disease

About Alnylam

Key Executives

Fundamentals

Valuation

Profitability

Trading

Technical indicators

Analyst views

Seasonality

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade